Ocular Trial Seen Appropriate Registrational Study in Wet AMD

 Clear Regulatory Path for AXPAXLI™ in Wet AMD Through Ongoing SOL-1 and SOL-R Registration-Enabling Trials

Ocular to Host a Q2 2024 Conference Call and Webcast Today, August 7th, at 8:00 AM ET

Ocular Therapeutix will host a conference call and webcast today at 8:00 AM ET to discuss recent business progress and financial results. To access the call, please dial: 1 (800) 343-4136 (United States) or 1 (203) 518-9843 (International) and reference the conference ID “OCULAR”. To access the webcast, please click here. The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for 90 days.

https://www.globenewswire.com/news-release/2024/08/07/2925816/0/en/Ocular-Therapeutix-Announces-FDA-Feedback-That-SOL-R-Trial-is-Appropriate-as-a-Registrational-Study-in-Wet-AMD.html